Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer
Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer
批准号:
10558559
负责人:
Jeremy James Johnson
金额:
$34.64万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-01-01 至 2023-12-31
关键词:
Androgen AntagonistsAndrogen ReceptorAnimal ModelAutomobile DrivingBindingCastrationCell NucleusChemicalsChemopreventionClinical TrialsCreativenessDevelopmentDiagnosisDimerizationDoseDrug KineticsEarly DiagnosisEnzymesEstrogen AntagonistsEvaluationEvolutionFDA approvedFosteringFruitFutureGRP78 geneGarcinia mangostanaGoalsHealthIn VitroIndividualLengthMalignant neoplasm of prostateMicrosomesMissionMolecularMolecular ChaperonesMusNatural Products ChemistryNuclear TranslocationOral AdministrationPharmaceutical PreparationsPharmacotherapyPhenotypePhosphotransferasesPreventionProliferatingPropertyProstate Cancer therapyPublic HealthRNA SplicingResearchResistanceResistance developmentRoleSourceStanoloneStructure-Activity RelationshipTestingTherapeuticTransgenic AnimalsUnited States National Institutes of HealthVariantXanthonesXenograft procedureabirateroneandrogeniccancer chemopreventioncastration resistant prostate cancerdietaryefficacy evaluationendoplasmic reticulum stressenzalutamideimprovedin vivoinnovationisoprenylationmalignant breast neoplasmmenmouse modelnovel strategiesnovel therapeutic interventionpreventprostate cancer cellprostate cancer riskprostate carcinogenesisside effectsmall moleculetransgenic adenocarcinoma of mouse prostatetreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The androgen receptor has been a target of prostate cancer for over 70 years with the evolution of
pharmacotherapy ranging from chemical castration, small molecular inhibition of anabolic enzymes, to blockade
of dihydrotestosterone. Despite the variety of these approaches none of these approaches are acceptable for
long term treatment across the prostate cancer continuum. Our long term goal is to identify dietary and semi-
synthetic xanthones that may inspire a new class of compounds as Selective Androgen Receptor Degraders
(SARDs) for prevention and/or treatment of prostate cancer including castration resistant prostate cancer. New
approaches are needed because FDA approved drugs for prostate cancer including enzalutamide and
abiraterone can develop resistance in as little as 3-6 months of therapy initiation. The mangosteen fruit is a rich
source of xanthones including α-mangostin, gartanin and others with more than 80 unique xanthones identified.
α-Mangostin and gartanin were chosen from 9 xanthones for our preliminary studies to evaluate xanthones as
SARDs. Using an approach incorporating natural products chemistry isolation we will create 4 different
mangosteen extracts with different xanthones. We will fully characterize these extracts chemically and
mechanistically for AR and AR splice variant (i.e. including AR-V7 a marker of resistance) degradation in vitro
and in vivo as well as pharmacokinetic properties including dosing parameters, microsome analysis and p450
interactions. Our central hypothesis is that mangosteen derived xanthones are SARDs that bind to the AR
preventing the nuclear translocation and dimerization of AR. Additionally, selected xanthones inhibit kinases
that have been shown to post-translationally modify AR. This leads to a decrease in proliferation inducing
endoplasmic reticulum stress. The chaperone protein BiP, a marker of endoplasmic reticulum stress, is activated
and binds AR directly leading to proteolytic degradation of wild type AR and AR-V7 (a splice variant of AR
responsible for anti-androgen resistance). Our objective in this proposal is to identify xanthones with the greatest
potential for broad application across the prostate carcinogenesis continuum spanning diagnosis to castration
resistance prostate cancer similar to anti-estrogens used to treat prostate cancer. Specific Aim 1. Elucidate
how α-mangostin and gartanin disrupt the functionality and translocation of the androgen receptor to the nucleus
leading to the proteasomal degradation of androgen receptor. Specific Aim 2. Identify the most active
mangosteen extract for AR degradation disruption using a xenograft mouse model while characterizing the
pharmacokinetic parameters of xanthones. Specific Aim 3. Determine if oral administration of a well-defined
mangosteen fruit extract will inhibit the development of LG-PIN to HG-PIN to prostate cancer in TRAMP mice
through disruption of AR.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Rosemary (Salvia rosmarinus): Health-promoting benefits and food preservative properties.
迷迭香(Salvia rosmarinus):具有促进健康的功效和食品防腐特性。
DOI:
--
发表时间:
2021
期刊:
International journal of nutrition
影响因子:
--
作者:
[Veenstra,JacobP, Johnson,JeremyJ]
通讯作者:
Johnson,JeremyJ
Covalent Modification of Proteins by Plant-Derived Natural Products: Proteomic Approaches and Biological Impacts.
植物源性天然产物对蛋白质的共价修饰:蛋白质组学方法和生物学影响。
DOI:
10.1002/pmic.201900386
发表时间:
2021-03
期刊:
Proteomics
影响因子:
3.4
作者:
[Tocmo R, Veenstra JP, Huang Y, Johnson JJ]
通讯作者:
Johnson JJ
DOI:
10.3390/nu13030773
发表时间:
2021-02-27
期刊:
Nutrients
影响因子:
5.9
作者:
[Veenstra JP, Vemu B, Tocmo R, Nauman MC, Johnson JJ]
通讯作者:
Johnson JJ
DOI:
10.3390/nu13093156
发表时间:
2021-09-10
期刊:
Nutrients
影响因子:
5.9
作者:
[Huang Y, Tocmo R, Nauman MC, Haughan MA, Johnson JJ]
通讯作者:
Johnson JJ
Prenylated xanthones from mangosteen (Garcinia mangostana) activate the AhR and Nrf2 pathways and protect intestinal barrier integrity in HT-29 cells.
从Mangosteen(Garcinia Mangostana)中的原酰化的黄色thone激活了AHR和NRF2途径,并保护HT-29细胞中的肠道屏障完整性。
DOI:
10.1016/j.freeradbiomed.2020.11.018
发表时间:
2021-02-01
期刊:
Free radical biology & medicine
影响因子:
7.4
作者:
[Tocmo R, Le B, Heun A, van Pijkeren JP, Parkin K, Johnson JJ]
通讯作者:
Johnson JJ
共 10 条
Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer
-
批准号:10321238
-
项目类别:
-
资助金额:$35.34万
-
财政年份:2019
-
负责人:Jeremy James Johnson
-
依托单位:
Mangostin: A Dietary-Based Xanthone For Prostate Cancer Chemoprevention
-
批准号:8214201
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2009
-
负责人:Jeremy James Johnson
-
依托单位:
Mangostin: A Dietary-Based Xanthone For Prostate Cancer Chemoprevention
-
批准号:7789273
-
项目类别:
-
资助金额:$7.43万
-
财政年份:2009
-
负责人:Jeremy James Johnson
-
依托单位:
海外基金